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ABSTRACT 
Chronic lymphocytic leukemia [CLL] is the most com- 
mon adult leukemia and is heterogeneous in clinical 
presentation. CLL cases present with various chro- 
mosomal aberrations, including 11q23, 14q32, 17p, 
and trisomy 12, with the most common abnormality 
being deletion of 13q14 [1]. Although monoallelic de- 
letion of 13q14 is common, there is a subset of pa- 
tients who have complete nullisomy at 13q14, a locus 
that has been hypothesized to contribute to CLL pa- 
thogenesis [2] due to loss of tumor suppressors [DLEU 
and miR-15a/16-1]. We hypothesized that deletion of 
both copies of 13q14 would lead to uncontrollable 
proliferation of CLL cells and a poor prognosis. We 
examined our 13q14 nullisomy for survival, treat- 
ment-free survival, lymphocyte doubling time, and 
the presence of lymphadenopathy. Furthermore, we 
compared the gene expression profiles between pa- 
tients with 13q14 monosomy, nullisomy, or normal 
karyotype. Our results suggest that patients with 13q 
nullisomy have a higher incidence of bulky lympha- 
denopathy [16.6% compared to 10% of monosomy 
patients], a higher frequency of lymphocyte doubling 
time [27.7% compared to 7.4% of monosomy pa- 
tients], and a higher rate of needing treatment [50% 
compared to 18.5% of monosomy patients]. We ob- 
served deletion of DLEU1 and HTR2A, consistent 
with a gene dosage effect, and observed PRE-binding 
sites on DLEU1. Patients with homozygous deletion of 
13q14 had a worse prognosis compared to heterozy- 
gotes. Lastly, the DLEU1 locus is a possible “second 
hit” loss for CLL progression. 
 
Keywords: Chronic Lymphocytic Leukemia; Gene  
Expression; 13q14; Nullisomy; DLEU; Tolerogenic 
1. INTRODUCTION 
Chronic lymphocytic leukemia [CLL] is the most com- 
mon adult leukemia and is heterogenous in clinical pres- 
entation. Previous studies have focused on identifying 
prognostic markers such as CD38− and ZAP70-expres- 
sion, immunoglobulin mutational status, lymphocyte dou- 
bling time, presence of lymphadenopathy, and chromo- 
somal abnormalities to better group patients for therapy 
[1,2]. Patients with CLL may have none, one, or several 
of the following chromosomal abnormalities: del [11q23], 
del [13q14], del [17p], trisomy 12, and, less frequently, 
del [14q32]. However, there exists a cohort of patients 
with loss of both alleles at 13q14 [13q null] that is dis- 
tinct of patients with monosomy at this region [13q mono] 
and wild type [WT]. The 13q14 locus was hypothesized 
to contribute to CLL pathogenesis due to the loss of tu- 
mor suppressors, DLEU and miR-15a/16-1 [3-6]. We 
hypothesized that deletion of both copies of 13q14 would 
lead to uncontrollable proliferation of CLL cells and a 
poor prognosis. To test this hypothesis, we performed 
retrospective analyses with the data we accumulated 
from CLL patients cared for at the University of Ne-
braska Medical Center [UNMC]. 
2. PATIENTS AND METHODS 
2.1. Patient Samples 
All peripheral blood CLL [PB-CLL] samples were ob- 
tained by venipuncture, and the CLL cells from bone 
marrow [BM-CLL] and lymph node [LN-CLL] were 
collected from the excess tissue samples. All protocols 
were approved by the Institutional Review Board [IRB] 
and Scientific Review Committee [SRC] at UNMC. PB- 
CLL and BM-CLL cells were separated by using mag-
netic bead cell separation [Miltenyi Biotec, Auburn, CA, 
USA], and samples with 95% or greater CD5+CD19+ 
cells were used for analyses. To obtain LN-CLL cells, 
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serial sections of frozen lymph node biopsies were ob- 
tained from the UNMC tissue bank. Immunohistochem- 
istry was used to stain each section for CD5 and CD19 to 
identify areas of >90% CLL cells. The CLL cells were 
microdissected out for the analyses. 
2.2. Fluorescent in Situ Hybridization [FISH]  
and Microarray Analyses 
Fluorescent in situ hybridization [FISH] was used to de- 
termine chromosomal abnormalities in CLL cells as pre- 
viously described [7]. The annotated patient data was 
examined to determine the association between time to 
treatment, treatment-free survival, lymphocyte doubling 
time, and the presence of lymphadenopathy. Microarray 
analyses were used to determine differential expression 
of genes in a region of 13q suggested to be deleted in 
CLL [8,9]. 
Previously, a tolerogenic signature was associated with 
poor prognosis in CLL [9-12]. Genes from the tolero- 
genic signature were examined among patients with 13q 
null, 13q mono, and WT cases. Next, the genes within 
the 13q locus that were included in our array were clus- 
tered by CLL patients WT at this locus compared to 13q 
mono and 13q null. These results would describe whe- 
ther there was a gene copy effect between CLL cases 
with losses at this region, which would identify a candi- 
date tumor suppressor gene[s]. 
2.3. Examination of Regulatory Elements 
The sequence for DLEU1 was examined using Vista 
[pipeline.lbl.gov/cgi-bin/gateway2] and the University of 
California, Santa Cruz [UCSC] Genome Bioinformatics 
[genome.ucsc.edu] Programs. The entire coding and non- 
coding sequence of DLEU1 was blasted for the poly- 
comb response elements [PRE], including: GAF, G10, 
PHO, and Z binding sites. 
3. RESULTS AND DISCUSSION 
3.1. Prognosis for CLL Patients with 13q  
Nullisomy 
Our cohort of 13q null patients [n = 34] had divergent 
clinical characteristics from that of 13q mono CLL cases 
[n = 27]. 13q null patients had higher incidences of bulky  
lymphadenopathy [16.6% null compared to 0% mono], 
shorter lymphocyte doubling time [27.7% null compared 
to 7.4% mono], and greater occurrences of needing treat- 
ment (50% null, 18.5% mono; Table 1). CLL patients 
were broadly defined as having a poor prognosis if there 
was lymph node-involvement, a short lymphocyte dou- 
bling time [defined as less than a year for doubling], and 
if they required treatment. Although CLL patients with 
13q deletion are generally classified as having a favor- 
able outcome, we suggest a divergence in prognosis be- 
tween patients with a heterozygous, compared to a ho- 
mozygous, deletion at this locus. Accordingly, patients 
with homozygous deletion of 13q14 might benefit from 
earlier treatment. 
We next examined the percentage of CLL cells with 
13q null to determine their susceptibility to treatment. 
The FISH results from pre-treatment and post-treatment 
for CLL patients showed a decrease in the number of 
CLL cells positive for 13q14 nullisomy from 18% pre- 
treatment to only 5% patients after treatment (p = 0.015; 
Figure 1(a)). This 73% decline preliminarily suggests 
that early treatment of patients with 13q null could be 
beneficial. 
3.2. Gene Expression Profiles [GEP] of Patients  
with 13q Nullisomy 
In order to determine whether there was a divergence in 
GEP between WT, 13q null, and 13q mono cases, mi- 
croarray data were examined. Previously, we reported 
that a tolerogenic signature is indicative of patients with 
an unfavorable outcome compared to those with a more 
indolent disease [8]. Furthermore, based on clinical pro- 
gnostic indicators, our results suggested that CLL pa- 
tients with 13q14 null had a less favorable prognosis 
compared to those mono or WT. As a consequence, we 
examined the tolerogenic GEP between CLL cases WT, 
mono, or null at 13q14 to determine if this expression 
signature correlated with clinical outcome. We hypothe- 
sized that patients with 13q14 null would have higher 
expression of the tolerogenic signature compared to 13q 
mono or WT cases. 
Changes in the GEP were compared between 13 null, 
13q mono, and patients WT at the 13q14 locus (Figure 
1(b)). There was an increase in the immunosuppressive  
 
Table 1. Characteristics of CLL patients with 13q14 nullisomy compared to 13q14 heterozygous deletion. 
Chromosomal 
Aberration 
Avg Age at Diagnosis 
Diagnosis (Range) N (male) % Patients with BLA
% Patients with <1 
yr LDT 
% Patients ever 
Treated 
Avg Months to 
Treatment (Range)
13q14 wildtype 63.15 years (45 - 85) 34 (16) 23.5%* 17.6% 56.3% 40.75 (1 - 245) 
13q14 monosomy 62.03 years (46 - 79) 27 (13) 0% 7.4% 18.5% 57.1 (1 - 185) 
13q14 nulilsomy 63.1 years (48 - 84) 18 (11) 16.6% 27.7% 50% 39.56 (1 - 96) 
*Indicates patients with favorable chromosomal abnormality, but with a high percentage of CLL cells expressing CD38; BLA: Bulky lymphadenopathy. 
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Figure 1. Clinical and molecular characteristics of CLL patients with 13q14 nullisomy: (a) The 
change in the percentage of CLL cells positive for nullisomy at 13q14 pre- and post-treatment. 
The percentage of CLL cells positive for deletion at 13q14 as analyzed by FISH before and af- 
ter therapy. N = 5, P = 0.015; (b) Tolerogenic gene expression profiles between CLL patients 
WT at the 13q14 locus, heterozygous (13q mono), or bearing a homozygous deletion (13q null). 
The genes in our microarray within this region were compared between patients who are WT, 
have a heterozygous deletion, or with a homozygous deletion at this region. Cluster analysis 
was performed using Cluster 3.0 and Treeview software; (c) GEP of genes at the 13q14 locus 
among CLL patients who are WT, have a heterozygous deletion, or with a homozygous dele- 
tion at this region. The genes in our microarray within this region were compared between pa- 
tients who are WT, have a heterozygous deletion, or with a homozygous deletion at this region. 
Cluster analysis was performed using Cluster 3.0 and Treeview software; (d) Genes on 13q14 
that were on our microarray chip (not an exhaustive list). Of the genes in the 13q14 region 
commonly deleted in CLL, the genes listed above were on our microarray. We were able to de- 
termine the gene expression profile for these select genes for CLL patients with both copies of 
13q14 compared to those that were missing either one or both copies at this locus. 
 
molecules APC and TGFβ1 in 13q null CLL cases when 
compared to 13q mono cases. APC, a member of the Wnt 
signaling pathway, was shown to regulate cell migration 
and adhesion and colorectal cancer is associated with 
mutations in this gene [13,14]. TGFβ1 has been impli- 
cated in immunosuppression, in addition to cellular pro- 
liferation, differentiation, adhesion, and migration [15- 
20]. 
3.3. Gene Expression in CLL Cases Nullisomy,  
Monosomy, or WT at 13q14 
After determining a prognostic significance for complete 
loss of 13q14, the next objective was to identify whether 
a tolerogenic/immunosuppressive signature was differen- 
tially expressed in these cells. Supervised cluster analy- 
ses were performed on the genes included in our mi- 
croarray platform that were within the 13q14 locus [8; 
MWG Biotech, Germany, Human 10K oligo set A; Fig- 
ure 1(c)]. The expected result was to observe a dosage 
effect of genes within the deleted region at 13q14. To 
determine critical genes in the region of interest, we ex- 
pected patients WT at the locus to have high expression 
[red], those missing one copy [+/−] to have a lower ex- 
pression [lighter red or green], and individuals null at 
this region to have no expression of critical genes [black]. 
We anticipated the results of these analyses would de- 
termine a region that was commonly deleted in CLL that 
we could compare to other reports in the literature. 
The expression of two genes was consistent with the 
predicted expression pattern; these were HTR2A and DL- 
EU1 (Figure 1(c)). The location of HTR2A and DLEU1 
is depicted in Figure 1(d). 5-hydroxytryptamine [sero- 
tonin] receptor 2A [HTR2A], G-protein-coupled receptor, 
has never been reported as having a role in CLL. Fur- 
thermore, as serotonin functions as a neurotransmitter, its 
association with cancer pathophysiology is an inter- 
esting observation. The gene deleted in lymphocytic 
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leukemia 1 [DLEU1] is a long non-coding RNA [lnRNA] 
previously reported to participate in CLL [21-25]. Al- 
though there are only 15 published papers describing 
DLEU1 to date, early reports and observations show 
promise that the regulation of this lnRNA appears to 
have a great influence on CLL progression.  
Although the role of DLEU1 in CLL is still elusive, 
we searched the sequence of this region to gain greater 
insight. A polycomb response element [PRE] conserved  
sequence was identified, known to serve as an antagonist 
for epigenetic regulation of gene expression [26] within 
this region (Figure 2(a)). This region is a regulatory 
switchable element that influences the architecture of 
chromatin and the expression of nearby genes [27,28]. In 
this regard, DLEU1 is potentially a docking site for the 
polyhomeotic [PHO] protein. This evolutionarily con- 
served, regulatory system was identified in Drosophila. 
The mammalian homolog of PHO in Drosophila is the  
 
(a)
(b)
 
Figure 2. Polycomb response element binding site: (a) Putative PRE 
binding sites on the long noncoding RNA, DLEU1 at 13q14. The bind- 
ing sites for the GAGA factor (GAF; 29), G10, extended GAGA site 
(G10; 30), PHO consensus (31), and Zeste binding site (Z; 30) are high- 
lighted in the selected portion of the sequence as indicated by the legend. 
Due to the length of DLEU1, an abbreviated portion of the sequence is 
provided in this figure; (b) Hypothesized mechanism of regulation by 
DLEU1. DLEU1, a long non-coding RNA (lnRNA) deleted in CLL with 
unknown function. We have identified PRE binding sites on DLEU1 
and describe a hypothesized mechanism of DLEU1 regulating transcrip- 
tion to maintain homeostasis, but when DLEU1 is lost as in the case of 
13q null, then transcription is dysregulated and multiple “hits” to the 
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genome likely contribute to CLL progression.  
transcription factor YY1 [29]. Recently, a lnRNA was the 
link between copy number variation and a polycomb/ 
trithorax epigenetic switch in muscular dystrophy [26], 
and we suspect a similar switch may be occurring in 
CLL following the loss of regulation of the region con- 
taining DLEU1 (Figure 2(b)). This finding suggests a 
potential negative feedback loop with the binding of YY1 
to DLEU1 thereby regulating gene expression. Therefore, 
this finding would explain the over decade-long conun- 
drum of observing a deletion in this region, but being 
unable to identify a clear point mutation or tumor sup- 
pressor gene. 
In summary, this report describes an unfavorable 
prognosis for patients with biallelic deletion of 13q14, 
compared to 13q mono patients. However, the percent- 
age of CLL cells with 13q null decreased after treatment, 
suggesting that chemotherapy was effective at killing 
these malignant cells. GEP of patients with 13q null, 
compared to 13q mono, identified the overexpression 
APC and TGFβ1. Therefore, the upregulation of these 
immunoregulatory molecules in 13q null patients might 
lead to a greater immunosuppression in these cases. 
The limitation of this study is the number of cases 
examined. A larger cohort is needed to conclusively de- 
termine the biological relevance of DLEU1 in CLL cases 
with 13q14 null, but hopefully this study will serve as a 
basis for additional in-depth analyses. Previously, a 
similar study with a large sample size [n = 323] showed 
that a higher percentage of 13q null cells were associated 
with a significantly shorter time to treatment [6]. Simi- 
larly, we suggest that CLL patients with 13q null have a 
worse prognosis than patients that are mono or WT at 
13q14. Contrastingly, these data contradict those de- 
scribed earlier this year [30]. Garg et al. observed that 
the baseline characteristics between CLL cases with 
mono- or bi-allelic deletion of 13q differed only by 
ZAP70-expression and albumin levels [31]. This study 
differs from ours in that solely fluorescent in situ hy- 
bridization [FISH] was used to assess the genetic abnor- 
malities in CLL cells. Patients included in our study were 
first screened using both FISH and gene expression pro- 
filing. Therefore, this study presents a comprehensive 
picture as to the genetic abnormalities present within this 
frequently deleted region. 
It will be difficult to prove a role for the consensus 
sequence of DLEU1 in CLL without engineering a dele- 
tion at that region both in CLL samples and an in vivo 
animal model. While this manuscript was in preparation, 
Lia et al. (2012) published a report regarding this precise 
question [31]. Transgenic mice engineered to have loss 
of 13q14 had a shorter life expectancy, similar to our 
data from patients described in this report [31; Table 1]. 
The data presented herein suggest that, first, CLL cases 
show a heterozygous deletion at 13q14, and then a “sec- 
ond hit” or loss of the second allele [13q null] is neces- 
sary to take CLL from an indolent to an aggressive stage. 
Prospective studies are necessary to conclusively deter- 
mine this switch causing CLL cells to drive a more ag- 
gressive disease. 
4. SUMMARY 
The findings presented herein are significant in that they 
suggest a different way of classifying CLL cases with 
13q null. However, it is important to note the limitations 
with the sample size described in this study. Based on 
this small sample size, we suggest that patients with the 
deletion of both copies of 13q14 potentially need therapy 
initiated earlier than their heterozygous counterparts and, 
thus, might require more frequent monitoring of lym- 
phocyte counts. The influence of DLEU1 in CLL was 
reported previously, and the microRNAs in this region 
have been studied extensively [2-5]. However, this is the 
first report suggesting that regulatory elements, specifi- 
cally PRE-sequences, of DLEU1 might contribute as a 
“second hit” to lead to a more aggressive disease pro- 
gression for patients with CLL. 
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